Ketogenic diet for blood sugar side effects of pasireotide in acromegaly
Part of Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This study tests whether a low-carbohydrate ketogenic diet can help manage high blood sugar caused by the medication pasireotide, which is used to treat acromegaly. If you are being considered for or already taking pasireotide and your blood sugar is rising, this diet might help you avoid or reduce the need for diabetes medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with acromegaly that surgery could not fix or was not an option
- Your acromegaly is not well controlled with current treatments (first-generation somatostatin receptor ligands or second-line options)
- Your HbA1c (average blood sugar over 3 months) is below 6.2% at the start, or between 6.2% and 8.0% and can be stabilized below 6.2% with metformin
- You are not already taking pasireotide, or you are already on stable pasireotide and can join the observational part
- You have not had pituitary surgery in the last 6 months or radiation in the last 2 years
- You do not have type 1 diabetes, poor blood sugar control (HbA1c ≥9.0%), or other diabetes medications besides metformin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a ketogenic (very low-carb) diet can help lower IGF-I levels in people with acromegaly who are already on stable medication. If you have acromegaly and your IGF-I levels are still above normal despite treatment, this diet might offer an additional way to manage your condition.
This trial studies how pasireotide LAR—a drug that controls growth hormone levels—affects bone health in people with acromegaly whose disease is not well-controlled after 6 months of another therapy. It may help patients understand the bone benefits of switching to this treatment.
This study watches how patients with acromegaly respond to octreotide, a medication given as injections under the skin. Researchers will collect information about how well the treatment works and any side effects you experience.
This study tests a new drug called MAR002 to treat acromegaly, a hormone disorder caused by a pituitary tumor that makes too much growth hormone. The drug is designed to help lower hormone levels and improve symptoms.
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
This trial tests a long-acting form of octreotide, a medicine that lowers growth hormone levels, in people with active acromegaly. It aims to see if this treatment is safe and effective in controlling the disease.
Hear when a new Acromegaly Due to Pituitary Adenoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.